These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37067232)

  • 21. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates.
    Pizones J; Plotkin H; Parra-Garcia JI; Alvarez P; Gutierrez P; Bueno A; Fernandez-Arroyo A
    J Pediatr Orthop; 2005; 25(3):332-5. PubMed ID: 15832149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
    Shah I; Johari A
    Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment.
    Vuorimies I; Arponen H; Valta H; Tiesalo O; Ekholm M; Ranta H; Evälahti M; Mäkitie O; Waltimo-Sirén J
    Bone; 2017 Jan; 94():29-33. PubMed ID: 27725317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of bisphosphonates in children with osteogenesis imperfecta.
    Glorieux FH
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1491-5. PubMed ID: 11837505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
    Rauch F; Glorieux FH
    Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
    Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
    Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study.
    Zhang Y; Hu J; Lin X; Sun L; Yan S; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
    Front Endocrinol (Lausanne); 2022; 13():901925. PubMed ID: 36225201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric Hand and Wrist Fractures in Osteogenesis Imperfecta: An Analysis of Incidence, Patient-specific Risk Factors, and Fracture-specific Characteristics.
    Chhabra BN; Phillips T; Mitchell TW; Gattu N; Ezeokoli EU; Bell B
    J Pediatr Orthop; 2023 Sep; 43(8):e680-e685. PubMed ID: 37278060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olecranon Fractures in Pediatric Patients With Osteogenesis Imperfecta.
    Tayne S; Smith PA
    J Pediatr Orthop; 2019 Aug; 39(7):e558-e562. PubMed ID: 30628974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series.
    Andersen JD; Bünger MH; Rahbek O; Hald JD; Harsløf T; Langdahl BL
    Osteoporos Int; 2019 Feb; 30(2):513-517. PubMed ID: 30448959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New trends in the treatment of osteogenesis imperfecta type III - own experience.
    Jakubowska-Pietkiewicz E; Chlebna-Sokół D
    Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fracture Patterns Differ Between Osteogenesis Imperfecta and Routine Pediatric Fractures.
    Peddada KV; Sullivan BT; Margalit A; Sponseller PD
    J Pediatr Orthop; 2018 Apr; 38(4):e207-e212. PubMed ID: 29356793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone density, fractures and the associated factors in iranian children and adolescent with Osteogenesis Imperfecta.
    Mohsenzade P; Amirhakimi A; Honar N; Saki F; Omrani GHR; Dabbaghmanesh M
    BMC Pediatr; 2021 Jan; 21(1):37. PubMed ID: 33446151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.
    Trejo P; Rauch F
    Osteoporos Int; 2016 Dec; 27(12):3427-3437. PubMed ID: 27492436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of osteogenesis imperfecta with bisphosphonates].
    Tau C
    Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta.
    Gerber LH; Binder H; Berry R; Siegel KL; Kim H; Weintrob J; Lee YJ; Mizell S; Marini J
    Arch Phys Med Rehabil; 1998 Jan; 79(1):46-51. PubMed ID: 9440417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.